KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Non-Current Deffered Revenue (2019 - 2025)

West Pharmaceutical Services' Non-Current Deffered Revenue history spans 7 years, with the latest figure at $13.5 million for Q4 2025.

  • For Q4 2025, Non-Current Deffered Revenue fell 12.34% year-over-year to $13.5 million; the TTM value through Dec 2025 reached $13.5 million, down 12.34%, while the annual FY2025 figure was $13.5 million, 12.34% down from the prior year.
  • Non-Current Deffered Revenue for Q4 2025 was $13.5 million at West Pharmaceutical Services, roughly flat from $13.5 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $28.9 million in Q4 2021 and bottomed at $11.4 million in Q1 2025.
  • The 5-year median for Non-Current Deffered Revenue is $18.8 million (2023), against an average of $19.0 million.
  • The largest annual shift saw Non-Current Deffered Revenue increased 26.2% in 2021 before it tumbled 38.71% in 2025.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $28.9 million in 2021, then plummeted by 33.91% to $19.1 million in 2022, then fell by 2.62% to $18.6 million in 2023, then decreased by 17.2% to $15.4 million in 2024, then fell by 12.34% to $13.5 million in 2025.
  • Per Business Quant, the three most recent readings for WST's Non-Current Deffered Revenue are $13.5 million (Q4 2025), $13.5 million (Q3 2025), and $12.5 million (Q2 2025).